

<b>BSC2.13</b>	<b>Elective Invasive Coronary Angiography (ICA)</b>		
<b>Original Policy Date:</b>	August 1, 2020	<b>Effective Date:</b>	September 1, 2024
<b>Section:</b>	7.0 Surgery	<b>Page:</b>	Page 1 of 27

## Policy Statement

This medical policy is not intended to address prior authorization of ICA for acute coronary syndrome (ACS) or other high-risk situations as addressed in the [Policy Guidelines](#) section below. However, services provided without prior authorization (including inpatient care) are subject to post service review and are also subject to the criteria and definitions in this policy. Documentation of why the individual is thought to have ACS or other high-risk conditions is required to meet criteria.

- I. Elective (NOT emergent) Invasive Coronary Angiography (ICA) and catheterization may be considered **medically necessary** when **any** of the following documentation are met:
  - A. The individual is 18 years of age or younger
  - B. Congenital heart disease (CHD)
  - C. Heart failure (HF) (also known as Congestive Heart Failure or CHF) with reduced ejection fraction (40% or less)
  - D. Hypertrophic cardiomyopathy (HCM)
  - E. Kawasaki disease (KD) (also known as mucocutaneous lymph node syndrome)
  - F. Post-cardiac transplant in a individual who has not undergone coronary angiography in the previous six months
  - G. Pulmonary artery extrinsic compressions of left main coronary artery
  - H. Valvular heart disease requiring open surgical replacement
  - I. New onset or escalation of angina on optimal medical therapy and within 9 months of percutaneous coronary intervention (PCI)
  - J. Intolerance of or failure to respond to optimal medical treatment (see [Policy Guidelines section](#))
- II. Elective Invasive coronary angiography (ICA) and catheterization for known or suspected coronary artery disease (CAD) is considered **not medically necessary** for all other indications not meeting the medically necessary criteria, including but not limited to the results of computed tomography coronary artery calcium scores.

**NOTE:** Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

## Policy Guidelines

**Emergent catheterization to evaluate or treat an acute coronary syndrome meeting the definitions below or any of the following high-risk factors are not intended to be subject to review under this medical policy:**

### Acute Coronary Syndrome

- ST-elevation myocardial infarction (STEMI)
- Non-ST elevation myocardial infarction (NSTEMI)
- Unstable angina

### Unstable angina

- Typical\* (see table below) angina/ischemic symptoms suggestive of ACS but without troponin elevation (or only minimal elevation), with ECG (electrocardiogram) changes indicative of ischemia (e.g., ST segment depression or transient elevation; or new T wave inversion).
- Angina at rest: pain of typical\* nature but for prolonged periods of time (i.e., >20 minutes); Canadian Cardiovascular Society (CCS) grade IV

- New onset angina: recent (i.e., < 2 months) onset of severe angina (CCS grade III). Angina that occurs for the first time with heavy or moderate exertion and subsides with rest would be considered to be CCS grade I or II (see below in Guidelines section) and should undergo maximal medical therapy as a first step.
- Crescendo angina: previous typical angina that progressively increases over a short period of time in severity/intensity and at a lower level of exertion.

**Note: Other type of angina not considered to be unstable**

**Table PG1. Traditional Clinical Classification of Suspected Anginal Symptoms**

<b>*Typical angina</b>	Meets the following three characteristics: (i) Constricting discomfort in the front of the chest or in the neck, jaw, shoulder, or arm; (ii) Precipitated by physical exertion; (iii) Relieved by rest or nitrates within 5 min.
<b>Atypical angina</b>	Meets two characteristics of *typical angina
<b>Non-anginal chest pain</b>	Meets only one or none of the characteristics of *typical angina

### High Risk for Coronary Artery Disease

- Suspected high risk for CAD based on findings from noninvasive testing while on optimal medical therapy, as indicated by **any** of the following:
  - Echocardiographic wall motion abnormality involving greater than 2 segments
  - High-risk Duke Treadmill Score (DTS) (less than or equal to -11) (see Policy Guidelines section)
  - Left ventricular ejection fraction (LVEF) of 35% or less at rest
  - Stress electrocardiogram findings of ST-segment elevation, or ventricular arrhythmia, or at least 2 millimeter (mm) of ST-segment depression
  - Stress-induced large perfusion defect (especially if anterior) or multiple moderate size perfusion defects
  - Stress-induced left ventricular dysfunction (exercise LVEF less than 35%)
- Other evidence of high risk on myocardial perfusion imaging while on optimal medical therapy, as indicated by **any** of the following:
  - A large fixed perfusion defect with left ventricular dilatation or increased lung uptake of radioisotope
  - A stress-induced moderate perfusion defect with left ventricular dilatation or increased lung uptake of radioisotope
  - Left ventricular enlargement or transient post-stress ischemic left ventricular dilatation

### Post-Acute Myocardial Infarction

- Post-acute myocardial infarction (MI), for identifying and predicting high risk when **any** of the following are present:
  - Clinically significant heart failure during hospital course
  - Ischemia provoked by minimal exercise on noninvasive testing
  - Left ventricular ejection fraction (EF) of 45% or less, and individual unable to undergo noninvasive testing

### Other High-Risk Factors

- Cardiac risk assessment needed prior to surgery for solid organ transplant candidates and who do not otherwise qualify for ICA.
- Individual survived sudden cardiac arrest
- Suspected acute pericarditis, but signs and symptoms, troponin levels, and pattern of ST elevation cannot definitively rule out acute infarction

- PCI is indicated by Fractional Flow Reserve (FFR) by Coronary Computed Tomographic Angiography (CCTA), but further definition of coronary anatomy is needed prior to PCI
- An episode of persistent or sustained hemodynamic or ventricular electrical (rhythm) instability
- Sustained ventricular arrhythmia

**Note:** Cardiac risk assessments do not improve outcomes when done prior to high-risk non-cardiac surgery. For solid organ transplants it is industry standard, however, and likely to be overturned on appeal.

### Canadian Cardiovascular Society Angina Grading Scale

The Canadian Cardiovascular Society (CCS) Angina Grading Scale was created by CCS, a national voice for cardiovascular physicians and scientists in Canada. The CCS is a membership organization that represents more than 1,800 professionals in the cardiovascular field. Its mission is to promote cardiovascular health and care through knowledge translation, professional development and leadership in health policy.<sup>1</sup>

**Table PG2. Canadian Cardiovascular Society Grading of Angina Pectoris**

Grade	Description
<b>Class I</b>	Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina with strenuous or rapid or prolonged exertion at work or recreation.
<b>Class II</b>	Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.
<b>Class III</b>	Marked limitation of ordinary physical activity. Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace.
<b>Class IV</b>	Inability to carry on any physical activity without discomfort – anginal syndrome may be present at rest.

Campeau Lucien. Grading of angina pectoris.<sup>2,3</sup>

Available on the Canadian Cardiovascular Society Website at

[www.ccs.ca](http://www.ccs.ca).<sup>4</sup>

### Optimal Intensity of Anti-Anginal Therapy

Maximal anti-anginal therapy (referred to as “Optimal Medical Therapy” elsewhere in this document) consists of the continuous use of drugs from at least three of four anti-anginal classes (beta blockers, calcium channel blockers, sodium channel blockers, nitrates) titrated to maximal efficacy and/or tolerance. Minimal therapy is use of one class of anti-anginal drugs. ACC/AHA guidelines suggest that beta-blockers should be considered as initial therapy for chronic stable angina. Current practice guidelines indicate low- risk individuals with chronic stable angina should be treated initially with optimal medical therapy (OMT; see Table PG3 below) and lifestyle modification. An assumption is made that agents to treat hypertension and hyperlipidemia, as well as anti-platelet agents, are in use as indicated and also titrated to maximally efficacious and/or tolerated effect.

**Table PG3. Anti-Anginal Therapy and Optimal Dose Range\***

\*in individuals without kidney impairment, liver impairment, or rhythm related disorders

Therapeutic Class	Medication Name and Optimal Dose Range
<b>Beta Blockers</b>	<ul style="list-style-type: none"> <li>• Metoprolol Tartrate: 50-200mg twice daily</li> <li>• Metoprolol Succinate: 100-400mg daily</li> <li>• Atenolol: 50-200mg daily</li> <li>• Carvedilol: 25 to 50mg total daily dose</li> </ul>

Therapeutic Class	Medication Name and Optimal Dose Range
	<ul style="list-style-type: none"> <li>• Bisoprolol: 2.5-10mg daily</li> <li>• Propranolol: 80-320mg total daily dose</li> <li>• Nadolol: 40-240mg daily</li> <li>• Pindolol (off-label): 5mg-30mg twice daily</li> <li>• Acebutolol (off-label): 200mg three times daily, 1200mg maximum daily dose</li> </ul> <p>Goal: Titrate to maximum tolerated dose, resolution of angina, resting heart rate &lt; 60</p>
<b>Non-Dihydropyridine Calcium Channel Blockers</b>	<ul style="list-style-type: none"> <li>• Diltiazem: 240-360mg total daily dose</li> <li>• Verapamil (Extended Release): 180-480mg total daily dose</li> </ul> <p>Goal: Titrate to maximum tolerated dose, resolution of angina, resting heart rate &lt; 60</p>
<b>Dihydropyridine Calcium Channel Blockers</b>	<ul style="list-style-type: none"> <li>• Amlodipine: 5-10mg daily</li> <li>• Felodipine: 5-10mg daily</li> <li>• Nifedipine: 30-120mg daily</li> <li>• Isradipine (off-label): 2.5mg-10mg twice daily</li> <li>• Nicardipine: 20-40mg three times daily</li> </ul> <p>Goal: Titrate to maximum tolerated dose, resolution of angina</p>
<b>Nitrates</b>	<ul style="list-style-type: none"> <li>• Isosorbide Mononitrate (Extended Release): 60-120mg daily</li> <li>• Isosorbide Dinitrate (Immediate Release): 10-80mg three times daily</li> <li>• Isosorbide Dinitrate (Sustained Release): 40-160mg daily</li> </ul> <p>Goal: Titrate to maximum tolerated dose, resolution of angina</p>
<b>Sodium channel blockers</b>	<ul style="list-style-type: none"> <li>• Ranolazine 500mg-1000mg twice daily</li> </ul> <p>Goal: Titrate to maximum tolerated dose or resolution of angina</p>

### Duke Treadmill Score

The Duke Treadmill Score (DTS) is a weighted index combining treadmill exercise time using standard Bruce protocol, maximum net ST segment deviation (depression or elevation), and exercise-induced angina. It was developed to provide accurate diagnostic and prognostic information for the evaluation of individuals with suspected coronary heart disease.<sup>4</sup> The typical observed range of DTS is from -25 (highest risk) to +15 (lowest risk). A low DTS is actually better at excluding ischemic heart disease in women than men. The calculation is done based on the information obtained from an exercise test by this formula:

- $DTS = [\text{Exercise duration (minutes)}] - [5 \times (\text{maximal ST elevation or depression})] - [4 \times (\text{treadmill angina index})]$

**Table PG4. Duke Treadmill Score<sup>5</sup>**

Duke Treadmill Score Index	
<b>Ex Time</b>	Treadmill exercise time
<b>Max ST</b>	Maximum net ST deviation (except aVR)
<b>Angina Index</b>	Treadmill angina index: 0. No angina during exercise 1. Non-limiting angina

Duke Treadmill Score Index					
	2. Exercise limited angina				
DTS	Duke treadmill score				
Risk	Low risk		Score $\geq$ +5		
	Moderate risk		Score between +4 and -10		
	High risk		Score $\leq$ -11		
DTS Risk Category	1-Yr Mortality	No Stenosis $\geq$ 75%	1 VD $\geq$ 75%	2 VD $\geq$ 75%	3 VD $\geq$ 75% or LM $\geq$ 75%
<b>Men</b>					
Low	0.9%	52.6%	22.4%	13.6%	11.4%
Mod	2.9%	17.8%	15.6%	27.9%	38.7%
High	8.3%	1.8%	9.1%	17.5%	71.5%
<b>Women</b>					
Low	0.5%	80.9%	9.4%	6.2%	3.5%
Mod	1.1%	65.1%	14.2%	8.3%	12.4%
High	1.8%	10.8%	18.9%	24.3%	46%
DTS Risk Category	5-Yr Mortality	Score			
Low risk	3%	Score $\geq$ +5			
Moderate risk	10%	Score between +4 and -10			
High risk	35%	Score $\leq$ -11			

aVR: Augmented vector right

VD = Vessel Disease; LM = Left Main

### Coding

See the [Codes table](#) for details.

## Description

Coronary angiography is an invasive procedure that uses a special dye (contrast material) and X-Rays to see how blood flows through the arteries in the heart. Coronary angiography is often done along with cardiac catheterization. This is a procedure which measures pressures in the heart chambers. An area of the body (e.g., the arm or groin) is cleaned and numbed with a local numbing medicine (anesthetic). A thin hollow tube, called a catheter, is passed through an artery and carefully moves it up into the heart. X-ray images help the provider position the catheter. Once the catheter is in place, dye (contrast material) is injected into the catheter. X-ray images are taken to see how the dye moves through the artery. The dye helps highlight any blockages in blood flow. These images are used to detect blockages (coronary artery disease) or spasms of the coronary arteries. Images can help determine whether angioplasty (opening the blockage with a small balloon inserted through the catheters) and stent placement (small, expandable hollow mesh tubes to keep the coronary artery open) is needed or whether coronary artery bypass surgery should be done to get blood past the area of blockage.

## Related Policies

- Cardiac Applications of Positron Emission Tomography Scanning
- Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
- Elective Percutaneous Coronary Intervention (PCI)

## Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract

language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

## Regulatory Status

Invasive coronary angiography interventions (ICA) are surgical procedures, therefore are not regulated by the U.S. Food and Drug Administration (FDA).

## Rationale

### Background

Coronary angiography is an invasive procedure that includes fluoroscopy after injection of a type of dye that's visible to visualize the great vessels, chambers, and coronary vessels of the heart, as well as venous and arterial bypass grafts or other arterial conduits such as the mammary arteries. The test is generally done to see if there's a restriction in blood flow going to the heart.

Coronary angiography is part of a general group of procedures known as heart (cardiac) catheterizations. Cardiac catheterization procedures can both diagnose and treat heart and blood vessel conditions. A coronary angiogram, which can help diagnose heart conditions, is the most common type of cardiac catheterization procedure.

During a coronary angiogram, a type of dye that's visible by an X-ray machine is injected into the blood vessels of your heart. The X-ray machine rapidly takes a series of images (angiograms), offering a look at your blood vessels. If a blockage is found, a percutaneous coronary intervention (PCI) such as angioplasty may be done to open the blockage. This may be done during the same procedure or at a later time. If there are many blockages or blockages in certain areas, a coronary artery bypass graft (CABG) may be necessary.

Risks of coronary angiography include cardiac tamponade, arrhythmias, injury to a catheterized artery, low blood pressure, allergic reaction to contrast dye, excessive bleeding, kidney damage, stroke or heart attack.

Invasive coronary angiography remains the gold standard for visualization and characterization of the coronary anatomy.

### Literature Review

#### Congenital Heart Disease

Cardiac catheterization for the diagnosis and management of Congenital Heart Disease (CHD) has been increasingly supplemented by noninvasive diagnostic modalities; initially cardiac ultrasound and, more recently, computed tomography (CT) scanning and magnetic resonance imaging (MRI). Advances in these technologies have been logarithmic, and it is likely that in the coming decade both morphologic and functional assessments of this patient population will be increasingly accomplished noninvasively.<sup>6</sup>

Noninvasive methods increasingly limit the need for catheterization unless intervention is considered. Many simple congenital cardiac defects are now sent to surgery without catheterization. Cardiac catheterization and angiocardiology complement these noninvasive techniques in the evaluation of adults with suspected CHD.<sup>6,7</sup>

Noninvasive imaging is indicated in both children and adults before surgery when repair may involve the coronary arteries or because of chest pain. It may also be indicated for complex congenital heart disease, particularly when intracardiac shunting is present.<sup>8</sup>

The 2008 American College of Cardiology (ACC) and American Heart Association (AHA) Guidelines for adults with CHD suggest the use of diagnostic catheterization primarily to resolve specific issues related to surgical intervention (e.g., preoperative evaluation of coronary arteries, assessment of pulmonary vascular disease and its response to vasoactive agents for planned surgical intervention, and/or heart or heart/lung transplantation) and as an adjunct to noninvasive assessment of morphologic and/or functional characteristics of complex CHD (e.g., for delineating arterial and venous anatomy in patients with heterotaxy, patients who are candidates for a Fontan procedure, or patients who have had previous palliation in the form of a shunt). The evaluation for possible interventional catheterization is an increasingly common indication for diagnostic catheterization. Catheter intervention, for instance, is commonly sought as the treatment of choice for correcting valvular pulmonary stenosis or regurgitation, branch pulmonary stenosis, residual or recurrent aortic coarctation, and arteriovenous fistulae. Coil or device occlusion of lesions such as patent ductus or secundum ASD is another preferred intervention for treatment.<sup>7</sup>

Cardiac catheterization and coronary angiography may be indicated for accurate measurement of congenital pulmonary or aortic stenosis gradients and to delineate anatomy, as well as for accurate assessment of pulmonary artery (PA) pressure and pulmonary vascular resistance (PVR). Pulmonary angiography and right ventriculography are recommended for pulmonary stenosis in particular. For patients with repaired tetralogy of Fallot, coronary artery compression testing (via cardiac catheterization) is recommended prior to transcatheter valve replacement or right ventricle-to-pulmonary artery conduit stenting. For transposition of the great arteries, the authors note that it is reasonable to perform anatomic evaluation of coronary artery patency in asymptomatic adults following an arterial switch procedure; coronary angiography is recommended if this patency cannot be established noninvasively. Cardiac catheterization can also be useful in the assessment of coarctation and recoarctation of the aorta, of sinus venosus defects and coronary anomalies, and of vascular rings.<sup>9</sup>

### **Heart Failure or Cardiomyopathy**

Coronary angiography is indicated to rule out an ischemic cause of heart failure (HF) or cardiomyopathy (CM), as noninvasive imaging is neither sensitive nor specific in this situation. If not already performed in the hospital, coronary angiography is appropriate for some patients following a myocardial infarction, including those with an ejection fraction of 35% or less, or those who have left ventricular aneurysm.<sup>10</sup>

In patients with known CAD and angina or with significant ischemia diagnosed by electrocardiogram (ECG) or noninvasive testing and impaired ventricular function, coronary angiography is indicated. Among those without a prior diagnosis, CAD should be considered as a potential etiology of left ventricular dysfunction (LVD) and should be excluded wherever possible. Coronary angiography may be considered in these circumstances to detect and localize large-vessel coronary obstructions. In patients in whom CAD has been excluded as the cause of LV dysfunction, coronary angiography is generally not indicated unless a change in clinical status suggests interim development of ischemic disease.<sup>10</sup>

The American College of Cardiology Foundation, in collaboration with the Society for Cardiovascular Angiography and Interventions and key specialty and subspecialty societies, conducted a review of common clinical scenarios where diagnostic catheterization is frequently considered. The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining the implementation of noninvasive imaging appropriate use criteria. The 166 indications were developed by a diverse

writing group and scored by a separate independent technical panel on a scale of 1 to 9, to designate appropriate use (median 7 to 9), uncertain use (median 4 to 6), and inappropriate use (median 1 to 3). Diagnostic catheterization may include several different procedure components. The indications developed focused primarily on 2 aspects of diagnostic catheterization. Many indications focused on the performance of coronary angiography for the detection of coronary artery disease with other procedure components (e.g., hemodynamic measurements, ventriculography) at the discretion of the operator. The majority of the remaining indications focused on hemodynamic measurements to evaluate valvular heart disease, pulmonary hypertension, cardiomyopathy, and other conditions, with the use of coronary angiography at the discretion of the operator. Seventy-five indications were rated as appropriate, 49 were rated as uncertain, and 42 were rated as inappropriate. The appropriate use criteria for diagnostic catheterization have the potential to impact physician decision making, healthcare delivery, and reimbursement policy. Furthermore, recognition of uncertain clinical scenarios facilitates identification of areas that would benefit from future research.<sup>11</sup>

The 2012 Canadian Cardiovascular Society Heart Failure (HF) guidelines state that cardiac catheterization and coronary angiography are appropriate for the evaluation of ischemia in heart failure patients.<sup>12</sup>

Coronary angiography is recommended in patients with HF who suffer from angina pectoris recalcitrant to medical therapy, provided the patient is otherwise suitable for coronary revascularization. Coronary angiography is also recommended in patients with a history of symptomatic ventricular arrhythmia or aborted cardiac arrest. Coronary angiography should be considered in patients with HF and intermediate to high pre-test probability of CAD and the presence of ischemia in non-invasive stress tests in order to establish the ischemic etiology and CAD severity.<sup>13</sup>

### **Hypertrophic Cardiomyopathy**

Invasive coronary angiography is indicated in patients with Hypertrophic Cardiomyopathy (HCM) and should be a routine accompaniment to an invasive catheterization performed in a patient with HCM for assessment of hemodynamic status and in such cases, should generally be performed after documentation of hemodynamics so as not to influence important measurements such as the magnitude of the LVOT gradient. When catheterization is performed, invasive coronary angiography should be undertaken before alcohol septal ablation in order to define the anatomy of the septal perforators in detail and exclude obstructive coronary stenoses. Furthermore, if alcohol septal ablation is being considered, the decision may be influenced by the location and extent of coronary disease as defined by coronary angiography.<sup>14</sup>

### **Kawasaki Disease**

Kawasaki disease (KD) is associated with coronary artery aneurysms, for which coronary angiography is useful for definitive imaging of the coronary arteries and great vessels. The standard for coronary artery assessment, particularly in the adult patient, is invasive angiography. It provides a detailed image of the coronary artery lumen and is very useful in defining regional flow-limiting stenoses and assessing them for potential intervention. Fractional flow reserve, measured during angiography, is a common method for determining the ischemia-causing potential of atherosclerotic stenoses. Discrete coronary artery stenosis in KD can also be assessed, with similar cut points as in adults with atherosclerosis. An additional insight from fractional flow reserve (FFR) in KD relates to the impact of coronary artery aneurysms on the arterial pressure. Turbulence-related pressure loss at dilated segments may create a drop in pressure along the artery, but FFR assessed in a small series of KD-associated aneurysms documented pressure drops that were smaller than threshold values used to predict pathophysiological importance. Patients with evidence of inducible myocardial ischemia on testing should undergo invasive coronary angiography. Although invasive coronary angiography is rarely performed during the acute phase of Kawasaki disease, angiography can be useful for later identification and periodic surveillance of coronary artery aneurysms, particularly when signs of ischemia are present. The adult with a known remote history of KD presenting with ST-



elevation myocardial infarction (STEMI) should be referred for emergency coronary angiography and determination of the best mode of revascularization. Unlike the patient in the acute/subacute phase of KD presenting with STEMI, the adult presenting with STEMI may have typical atherosclerotic disease as the cause of their STEMI, and standard percutaneous coronary intervention (PCI) techniques may be appropriate. If the patient is found to have an acutely thrombosed aneurysm, then a judgment decision will need to be made by the interventional cardiologist as to whether PCI should be attempted or a pharmacological strategy should be used.<sup>15</sup>

### Post-Cardiac Transplant

Coronary angiography coupled with assessment of cardiac allograft function maintains the highest level of evidence and consensus opinion for inclusion in the final nomenclature. The advantages of angiography are that it is universal in availability for both adult and pediatric patients, clinically accepted, and applicable at any time in the post-transplantation process (favorable for longitudinal and snap-shot assessments).<sup>16</sup>

There are distinct difficulties with the performance of invasive tests in children. In experienced hands, coronary angiography, including selective ostial injection, is technically feasible with a low complication rate. The highest risk is in the infant population, generally considered to have a weight of less than 10 kg. Femoral arterial thrombus formation is a risk, especially in smaller patients. Many pediatric centers perform coronary angiography under a general anesthetic in a significant proportion of their pediatric transplant patients. Technical expertise and facilities exist in all pediatric heart transplant centers.<sup>16</sup>

It has been noted that a major cause of death in post-transplant patients is coronary artery vasculopathy, and cardiac catheterization with intravascular ultrasound is useful for surveillance of cardiac allograft vasculopathy (CAV) and silent obstructive coronary artery disease.<sup>17,18</sup> Right heart catheterization is useful for hemodynamic assessment in post-transplant patients and to facilitate endomyocardial biopsy to provide histologic monitoring for transplant rejection.<sup>18</sup>

### Pulmonary Artery Extrinsic Compression

Coronary angiography has limitations in evaluating left main coronary artery (LMCA) stenosis. Intracoronary imaging techniques such as intravascular ultrasound (IVUS) can provide critical information in this scenario. An IVUS minimal lumen area of 6 mm<sup>2</sup> is a safe cutoff value for deferring revascularization in LMCA disease. Furthermore, the lack of correlation between coronary angiography and IVUS measurements is well known. In the LITRO (studio de Lesiones Intermedias de TRonco) study, 43% of patients with angiographic stenosis >50% showed a minimal lumen area >6 mm<sup>2</sup>.<sup>19</sup> This cutoff value also predicts the physiological significance of LMCA stenosis assessed by fractional flow reserve. The correlation between CA and IVUS is even poorer in ostial LMCA stenosis. The role of IVUS in LMCA external compression could be particularly important due to the limited value of noninvasive ischemia detection techniques in identifying candidates to revascularization. Therefore, coronary angiography could be insufficient to clarify the severity and/or functional implications of the LMCA stenosis in this clinical setting. This could lead to unnecessary interventions with subsequently higher rates of complications. The authors report a prevalence of significant LMCA compression by an enlarged pulmonary artery of 6% in the overall PAH population. However, this finding has been described also in asymptomatic patients who are at risk of developing ventricular arrhythmias and sudden death. Therefore, screening programs should target all PAH patients independently of the clinical status to avoid LMCA compression overlooking.<sup>20</sup>

### Valvular Heart Disease

Coronary angiography is indicated before valve intervention in **patients with symptoms of angina, objective evidence of ischemia, decreased Left Ventricular (LV) systolic function, history of CAD, or coronary risk factors (including men age >40 years and postmenopausal women)**. Coronary angiography can be avoided in young patients (men <40 years of age and premenopausal women) with no atherosclerotic risk factors and in patients in whom the risks outweigh the benefits, such as in

patients with acute aortic dissection, large aortic valve vegetation, or occlusive prosthetic thrombosis.<sup>21</sup>

Coronary angiography should be performed as part of the evaluation of patients with chronic severe secondary Mitral Regurgitation (MR). Surgery without coronary angiography is reasonable for patients having emergency valve surgery for acute valve regurgitation, disease of the aortic sinuses or ascending aorta, or infective endocarditis (IE).<sup>21</sup>

Cardiac catheterization may be indicated to assess hemodynamics, coronary artery anatomy, and severity of valve disease in the setting of equivocal echocardiographic evidence regarding the severity of valvular heart disease.<sup>21</sup>

## Coronary Artery Disease

### Duke Treadmill Score

Exercise testing is useful in the assessment of symptomatic patients for diagnosis of significant or extensive coronary disease and to predict their future risk of cardiac events. The Duke treadmill score (DTS) is a composite index that was designed to provide survival estimates based on results from the exercise test, including ST-segment depression, chest pain, and exercise duration. However, its usefulness for providing diagnostic estimates has yet to be determined.<sup>22</sup>

Mark et al (1987) evaluated 2842 consecutive patients with chest pain (CP) who had both treadmill testing and cardiac catheterization. The population was randomly divided into two equal-sized groups and the Cox regression model was used in one to form a treadmill score that was then validated in the other group. The final treadmill score was calculated as follows: exercise time--(5 X ST deviation)--(4 X treadmill angina index). Using this treadmill score, 13% of the patients were found to be at high risk; 53%, at moderate risk; and 34%, at low risk. The treadmill score added independent prognostic information to that provided by clinical data, coronary anatomy, and left ventricular ejection fraction: patients with three-vessel disease with a score of -11 or less had a 5-year survival rate of 67%, and those with a score of +7 or more had a 5-year survival rate of 93%. The treadmill score was useful for stratifying prognosis in patients with suspected coronary artery disease who were referred for catheterization, and may provide a useful adjunct to clinical decision making in the larger population of patients being evaluated for chest pain.<sup>23</sup>

Coronary angiography is designed to provide detailed information about the size and distribution of coronary vessels, the location and extent of atherosclerotic obstruction, and the suitability for revascularization. The LV angiogram, usually performed with coronary angiography, provides an assessment of the extent of focal and global LV dysfunction and of the presence and severity of coexisting disorders (e.g., valvular or other associated lesions). Patients with non-ST-elevation acute coronary syndrome (NSTEMI-ACS) can be divided into risk groups on the basis of their initial clinical presentation.<sup>24,25</sup>

Risk stratification identifies patients who are most likely to benefit from subsequent revascularization. Patients with left main disease or multivessel CAD with reduced LV function are at high risk for adverse outcomes and are likely to benefit from CABG. Clinical evaluation and noninvasive testing aid in the identification of most patients at high risk because they often have  $\geq 1$  of the following high-risk features: advanced age (>70 years of age), prior MI, revascularization, ST deviation, HF, depressed resting LV function (i.e., LVEF  $\leq 0.40$ ) on noninvasive study, or noninvasive stress test findings, including magnetic resonance imaging.<sup>26</sup> Any of these risk factors or diabetes mellitus may aid in the identification of high-risk patients who could benefit from an invasive strategy.<sup>24</sup>

Some patients with NSTEMI-ACS are not in the very high-risk group and do not have findings that portend a high risk for adverse outcomes. They are not likely to receive the same degree of benefit from routine revascularization afforded to high-risk patients, and an invasive study is optional for

those at lower risk and can be safely deferred pending further clinical evidence. Decisions about coronary angiography in patients who are not at high risk according to findings on clinical examination and noninvasive testing can be individualized on the basis of patient preferences and/or symptoms.<sup>24</sup>

In contrast to noninvasive tests, coronary angiography provides detailed structural information for assessment of prognosis and appropriate management. When combined with LV angiography, it also provides an assessment of global and regional LV function. Coronary angiography is usually indicated in patients with NSTEMI-ACS who have recurrent symptoms or ischemia despite adequate medical therapy or who are at high risk as categorized by clinical findings (HF, serious ventricular arrhythmias), noninvasive test findings (significant LV dysfunction with EF <0.40, large anterior or multiple perfusion defects or wall motion abnormalities on echocardiography, high-risk Duke treadmill score  $\leq -11$ ), high-risk TIMI or GRACE scores, or markedly elevated troponin levels. Patients with NSTEMI-ACS who have had previous PCI or CABG should also be considered for early coronary angiography, unless prior coronary angiography data indicate that no further revascularization is feasible.<sup>24</sup>

The general indications for coronary angiography and revascularization should be tempered by individual patient characteristics and preferences (a patient-centered approach). Patient and clinician judgments about risks and benefits are important for patients who might not be candidates for coronary revascularization, such as very frail older adults and those with serious comorbid conditions (e.g., severe hepatic, pulmonary, or renal failure; active or inoperable cancer).<sup>24</sup>

According to Deharo et al (2017), in patients with non-ST-segment-elevation myocardial infarction (NSTEMI) and GRACE (Global Registry of Acute Coronary Events) score >140, coronary angiography (CAG) is recommended by European and American guidelines within 24 hours. The trial's objective was to study the association of very early (i.e.,  $\leq 12$  hours), early (12-24 hours), and delayed (>24 hours) CAG in patients with NSTEMI with GRACE score >140 with ischemic outcomes. The TAO trial (Treatment of Acute Coronary Syndrome With Otamixaban) randomized patients with NSTEMI and CAG scheduled within 72 hours to heparin plus eptifibatid versus otamixaban. In this post hoc analysis, patients with a GRACE score >140 were categorized into 3 groups according to timing of CAG from admission (<12,  $\geq 12$ -<24, and  $\geq 24$  hours). The primary ischemic outcome was the composite of all-cause death and myocardial infarction within 180 days of randomization. CAG was performed in 4071 patients (<12 hours, n=1648 [40.5%]; 12-24 hours, n=1420 [34.9%];  $\geq 24$  hours, n=1003 [24.6%]). With CAG  $\geq 24$  hours as a reference, CAG from 12 to 24 hours was not associated with a lower risk of primary ischemic outcome at 180 days (odds ratio, 0.96; 95% confidence interval, 0.75-1.23), whereas CAG <12 hours was associated with a lower risk of death and myocardial infarction (odds ratio, 0.71; 95% confidence interval, 0.55-0.91). Performing CAG <12 hours was also associated with a lower risk of death and myocardial infarction (odds ratio, 0.76; 95% confidence interval, 0.61-0.94; P=0.01) compared with CAG performed at 12 to 24 hours. No difference was observed in bleeding complications. The study showed that in patients with high-risk NSTEMI, undergoing CAG within the initial 12 hours after admission (as opposed to later, either 12-24 or  $\geq 24$  hours) was associated with lower risk of ischemic outcomes at 180 days.<sup>27</sup>

### Early Invasive and Ischemia-Guided Strategies: Recommendations<sup>24</sup>

#### *Class I*

1. An urgent/immediate invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in patients (men and women) with NSTEMI-ACS who have refractory angina or hemodynamic or electrical instability (without serious comorbidities or contraindications to such procedures).<sup>28,29,30,31</sup> (Level of Evidence: A)
2. An early invasive strategy (diagnostic angiography with intent to perform revascularization if appropriate based on coronary anatomy) is indicated in initially stabilized patients with

NSTE-ACS (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events (see Table 1).<sup>28,29,30,31,32,33,38</sup> (*Level of Evidence: B*)

*Class IIa*

1. It is reasonable to choose an early invasive strategy (within 24 hours of admission) over a delayed invasive strategy (within 25 to 72 hours) for initially stabilized high-risk patients with NSTE-ACS. For those not at high/intermediate risk, a delayed invasive approach is reasonable.<sup>34</sup> (*Level of Evidence: B*)

*Class IIb*

1. In initially stabilized patients, an ischemia-guided strategy may be considered for patients with NSTE-ACS (without serious comorbidities or contraindications to this approach) who have an elevated risk for clinical events.<sup>31,32</sup> (*Level of Evidence: B*)
2. The decision to implement an ischemia-guided strategy in initially stabilized patients (without serious comorbidities or contraindications to this approach) may be reasonable after considering clinician and patient preference. (*Level of Evidence: C*)

*Class III: No Benefit*

1. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is not recommended in patients with:
  - a. Extensive comorbidities (e.g., hepatic, renal, pulmonary failure; cancer), in whom the risks of revascularization and comorbid conditions are likely to outweigh the benefits of revascularization. (*Level of Evidence: C*)
  - b. Acute chest pain and a low likelihood of ACS who are troponin-negative (*Level of Evidence: C*), especially women.<sup>35</sup> (*Level of Evidence: B*)

**Table 1. Factors Associated with Appropriate Selection of Early Invasive Strategy or Ischemia-Guided Strategy in Patients with NSTE-ACS**

<b>Immediate invasive (within 2 hr.)</b>	<ul style="list-style-type: none"> <li>• Refractory angina</li> <li>• Signs or symptoms of HF or new or worsening mitral regurgitation</li> <li>• Hemodynamic instability</li> <li>• Recurrent angina or ischemia at rest or with low-level activities despite intensive medical therapy</li> <li>• Sustained VT or VF</li> </ul>
<b>Ischemia-guided strategy</b>	<ul style="list-style-type: none"> <li>• Low-risk score (e.g., TIMI [0 or 1], GRACE [<math>&lt;109</math>])</li> <li>• Low-risk Tn-negative female patients</li> <li>• Patient or clinician preference in the absence of high-risk features</li> </ul>
<b>Early invasive (within 24 hr.)</b>	<ul style="list-style-type: none"> <li>• None of the above, but GRACE risk score <math>&gt;140</math></li> <li>• Temporal change in Tn</li> <li>• New or presumably new ST depression</li> </ul>
<b>Delayed invasive (within 25–72 hr.)</b>	<ul style="list-style-type: none"> <li>• None of the above but diabetes mellitus</li> <li>• Renal insufficiency (GFR <math>&lt;60</math> mL/min/1.73 m<sup>2</sup>)</li> <li>• Reduced LV systolic function (EF <math>&lt;0.40</math>)</li> <li>• Early postinfarction angina</li> <li>• PCI within 6 mo.</li> <li>• Prior CABG</li> <li>• GRACE risk score 109–140; TIMI score <math>\geq 2</math></li> </ul>

CABG indicates coronary artery bypass graft; EF, ejection fraction; GFR, glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events<sup>29</sup>; HF, heart failure; LV, left ventricular; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; TIMI, Thrombolysis In Myocardial Infarction<sup>28</sup>; Tn, troponin; VF, ventricular fibrillation; and VT, ventricular tachycardia.

Several studies and meta-analyses have concluded that a strategy of routine invasive therapy is generally superior to an ischemia-guided strategy or selectively invasive approach.<sup>35,36</sup> One study reported that the routine invasive strategy resulted in an 18% relative reduction in death or MI,

including a significant reduction in MI alone.<sup>37</sup> The routine invasive arm was associated with higher in-hospital mortality (1.8% versus 1.1%), but this disadvantage was more than compensated for by a significant reduction in mortality between discharge and the end of follow-up (3.8% versus 4.9%). The invasive strategy was also associated with less angina and fewer rehospitalizations. Patients undergoing routine invasive treatment also had improved quality of life. In an analysis of individual patient data<sup>36</sup> (Fox KA et al. 2010) that reported 5-year outcomes from the FRISC (Framingham and Fast Revascularization During Instability in Coronary Artery Disease)-II trial<sup>38</sup>, ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial<sup>31</sup>, and RITA (Randomized Trial of a Conservative Treatment Strategy Versus an Interventional Treatment Strategy in Patients with Unstable Angina)-3 trial<sup>33</sup>, 14.7% of patients (389 of 2721) randomized to a routine invasive strategy experienced cardiovascular death or nonfatal MI versus 17.9% of patients (475 of 2746) in the selective invasive strategy (HR: 0.81; 95% CI: 0.71 to 0.93;  $P=0.002$ ). The most marked treatment effect was on MI (10.0% routine invasive strategy versus 12.9% selective invasive strategy), and there were consistent trends for fewer cardiovascular deaths (HR: 0.83; 95% CI: 0.68 to 1.01;  $P=0.068$ ) and all-cause mortality (HR: 0.90; 95% CI: 0.77 to 1.05). There were absolute reductions of 2.0% to 3.8% in cardiovascular death or MI in the low- and intermediate-risk groups and an 11.1% absolute risk reduction in the highest-risk patients. The invasive strategy demonstrated its greatest advantage in the highest-risk stratum of patients with no significant benefit on mortality over the noninvasive approach in moderate- and low-risk patients.<sup>39</sup> An ischemia-guided strategy has been used with favorable results in initially stabilized patients with NSTEMI-ACS at elevated risk for clinical events, including those with positive troponin levels.<sup>31</sup> One limitation of these studies is the absence of adherence to optimal medical therapy in non-invasively treated patients during long-term management. In addition, in FRISC-II, invasive management was delayed and patients with markedly positive stress tests (up to 2.9-mm exercise-induced ST depression) were randomized to noninvasive or invasive therapy.<sup>24</sup>

Maddox et al (2014) published a retrospective cohort study of all US veterans undergoing elective coronary angiography for CAD between October 2007 and September 2012 in the Veterans Affairs health care system. Patients with prior CAD events were excluded. Among 37,674 patients, 8384 patients (22.3%) had nonobstructive CAD and 20,899 patients (55.4%) had obstructive CAD. Within 1 year, 845 patients died and 385 were rehospitalized for MI. Among patients with no apparent CAD, the 1-year MI rate was 0.11% ( $n = 8$ , 95% CI, 0.10%-0.20%) and increased progressively by 1-vessel nonobstructive CAD, 0.24% ( $n = 10$ , 95% CI, 0.10%-0.40%); 2-vessel nonobstructive CAD, 0.56% ( $n = 13$ , 95% CI, 0.30%-1.00%); 3-vessel nonobstructive CAD, 0.59% ( $n = 6$ , 95% CI, 0.30%-1.30%); 1-vessel obstructive CAD, 1.18% ( $n = 101$ , 95% CI, 1.00%-1.40%); 2-vessel obstructive CAD, 2.18% ( $n = 110$ , 95% CI, 1.80%-2.60%); and 3-vessel or LM obstructive CAD, 2.47% ( $n = 137$ , 95% CI, 2.10%-2.90%). After adjustment, 1-year MI rates increased with increasing CAD extent. Relative to patients with no apparent CAD, patients with 1-vessel nonobstructive CAD had a hazard ratio (HR) for 1-year MI of 2.0 (95% CI, 0.8-5.1); 2-vessel nonobstructive HR, 4.6 (95% CI, 2.0-10.5); 3-vessel nonobstructive HR, 4.5 (95% CI, 1.6-12.5); 1-vessel obstructive HR, 9.0 (95% CI, 4.2-19.0); 2-vessel obstructive HR, 16.5 (95% CI, 8.1-33.7); and 3-vessel or LM obstructive HR, 19.5 (95% CI, 9.9-38.2). One-year mortality rates were associated with increasing CAD extent, ranging from 1.38% among patients without apparent CAD to 4.30% with 3-vessel or LM obstructive CAD. After risk adjustment, there was no significant association between 1- or 2-vessel nonobstructive CAD and mortality, but there were significant associations with mortality for 3-vessel nonobstructive CAD (HR, 1.6; 95% CI, 1.1-2.5), 1-vessel obstructive CAD (HR, 1.9; 95% CI, 1.4-2.6), 2-vessel obstructive CAD (HR, 2.8; 95% CI, 2.1-3.7), and 3-vessel or LM obstructive CAD (HR, 3.4; 95% CI, 2.6-4.4). Similar associations were noted with the combined outcome. The patients undergoing elective coronary angiography, nonobstructive CAD, compared with no apparent CAD, was associated with a significantly greater 1-year risk of MI and all-cause mortality. These findings suggest clinical importance of nonobstructive CAD and warrant further investigation of interventions to improve outcomes among these patients.<sup>40</sup>

Larson et al (2012) published a systematic review and meta-analysis to address the question: "In patients with return of spontaneous circulation following out-of-hospital cardiac arrest, does acute

coronary angiography with coronary intervention improve survival compared to conventional treatment?" Thirty-two non-randomized studies were included of which 22 were case-series without patients with conservative treatment. Seven studies with specific efforts to control confounding had statistical evidence to support the use of acute coronary angiography following resuscitation from out-of-hospital cardiac arrest. The remaining 25 studies were considered neutral. Following acute coronary angiography, the survival to hospital discharge, 30 days or six months ranged from 23% to 86%. In patients without an obvious non-cardiac etiology, the prevalence of significant coronary artery disease ranged from 59% to 71%. Electrocardiographic findings were unreliable for identifying angiographic findings of acute coronary syndrome. Ten comparison studies demonstrated a pooled unadjusted odds ratio for survival of 2.78 (1.89; 4.10) favoring acute coronary angiography. The authors of this review came to the conclusion that there are no randomized studies that exist on acute coronary angiography following out-of-hospital cardiac arrest. An increasing number of observational studies support feasibility and a possible survival benefit of an early invasive approach. In patients without an obvious non-cardiac etiology, acute coronary angiography should be strongly considered irrespective of electrocardiographic findings due to a high prevalence of coronary artery disease.<sup>41</sup>

Acute coronary thrombotic occlusion is the most common trigger of cardiac arrest leading Zanuttini et al (2012) to assess the impact of an invasive strategy characterized by emergency coronary angiography and subsequent percutaneous coronary intervention (PCI), if indicated, on in-hospital survival of resuscitated patients with out-of-hospital cardiac arrest (OHCA) and no obvious extracardiac cause who do not regain consciousness soon after recovery of spontaneous circulation. Ninety-three consecutive patients ( $67 \pm 12$  years old, 76% men) were included in the study. Clinical characteristics and coronary angiographic and in-hospital outcome data were retrospectively collected. Multivariate Cox proportional-hazards analysis was performed to identify independent determinants of in-hospital survival. Coronary angiography was performed in 66 patients (71%). Forty-eight patients underwent emergency coronary angiography; in the remaining 18 patients, mean time from OHCA to coronary angiography was  $13 \pm 10$  days. In patients referred to emergency coronary angiography, successful emergency PCI of a culprit coronary lesion was performed in 25 patients (52%). In-hospital survival rate was 54%. At multivariate analysis, emergency coronary angiography (hazard ratio 2.32, 95% confidence interval 1.23 to 4.38,  $p = 0.009$ ) and successful emergency PCI (hazard ratio 2.54, 95% confidence interval 1.35 to 4.8,  $p = 0.004$ ) were independently related to in-hospital survival in the overall study population; delay in performing coronary angiography (hazard ratio 0.95, 95% confidence interval 0.92 to 0.99,  $p = 0.013$ ) was independently related to in-hospital mortality in patients referred to coronary angiography. In conclusion, an invasive strategy characterized by emergency coronary angiography and subsequent PCI, if indicated, seems to improve in-hospital outcome of resuscitated but unconscious patients with OHCA without obvious extracardiac cause.<sup>42</sup>

Lee et al (2018) reported that the applicability of Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) scores to left main coronary artery disease (CAD) has been questioned. A simplified alternative is needed for guiding decision making; therefore the authors evaluated the prognostic value of a simplified angiographic classification in comparison with a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery score-based approach for patients with left main CAD undergoing drug-eluting stent implantation. The proposed approach classified left main CAD as either extensive ( $n=819$ ), defined as left main bifurcation lesions with an involvement of ostial left circumflex artery or as any left main lesion plus multivessel CAD, or limited ( $n=453$ ), defined as ostial/midshaft lesions or left main bifurcation lesions without an involvement of ostium of left circumflex artery, alone or plus 1-vessel disease. The databases from 4 prospective Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease studies were pooled, and the primary outcome was a major adverse cardiac event, defined as death, myocardial infarction, or repeat revascularization. During follow-up (median 38 months; interquartile range, 36-61 months), the risk for major adverse cardiac event was significantly higher with extensive

than with limited left main CAD (adjusted hazard ratio, 2.13; 95% confidence interval, 1.54-2.94;  $P < 0.001$ ). The risk for a composite outcome of death or myocardial infarction was also higher with extensive left main CAD (adjusted hazard ratio, 1.75; 95% confidence interval, 1.08-2.85;  $P = 0.02$ ). However, Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery score tertiles did not effectively stratify these 2 outcome measures. Compared with Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery scores, the simpler angiographic approach provided better discrimination for future cardiovascular events in patients with left main CAD undergoing drug-eluting stent implantation.<sup>43</sup>

Revascularization in stable ischemic heart disease (SIHD) is indicated in patients on optimal medical therapy with angina and/or demonstrable ischemia and a significant stenosis in one or more epicardial coronary arteries. Angiography alone, however, cannot accurately determine the hemodynamic significance of coronary lesions, particularly those of intermediate stenosis severity. A lesion may appear significant on coronary angiogram but may not have functional significance. Percutaneous coronary intervention (PCI) of functionally insignificant coronary artery lesions may have serious consequences; therefore, judicious decision-making in the cardiac catheterization laboratory is indicated. For this reason, it is becoming increasingly important to show that a stenosis is capable to induce myocardial ischemia prior to intervention. Fractional flow reserve (FFR) has emerged as a useful tool for this purpose.<sup>44</sup>

## References

1. Canadian Cardiovascular Society Angina Grading Scale. Accessed on August 16, 2024 from <http://www.ccs.ca/en/>.
2. Campeau Lucien. Grading of angina pectoris. *Circulation* 1976; 54:522-3.
3. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. *Can J Cardiol* 2002; 18(4):371-379.
4. Canadian Cardiovascular Society. Accessed on February 24, 2020 from [www.ccs.ca](http://www.ccs.ca). ACC/AHA 2002 Guideline Update for Exercise Testing: Summary Article. 2002; Vol 106, No.14. Accessed on August 16, 2024 from <https://www.ahajournals.org/doi/full/10.1161/01.cir.0000034670.06526.15>.
5. Chow CM, Brawer E, Ho E. Cardiomath. 2005-2011. Accessed on March 28, 2022 from <http://www.csecho.ca/wp-content/themes/twentyeleven-csecho/cardiomath/index.php?eqnHD=stress>.
6. Woodard PK, et al. Known or Suspected Congenital Heart Disease in the Adult. ACR Appropriateness Criteria. American College of Radiology (ACR). *J Am Coll Radiol*. 2017 May;14(5S):S166-S176. DOI:10.1016/j.jacr.2017.02.036.
7. Warnes, C.A., Williams, R.G., Bashore, T.M. et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2008; 118: 2395-2451.
8. Webb GD, Smallhorn JF, Therrien J, Redington AN. Congenital Heart Disease In the Adult and Pediatric Patient. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, editors. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 11th ed. Philadelphia, PA: Elsevier; 2019:1519-1573.
9. Stout KK, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology* 2018; DOI: 10.1016/j.jacc.2018.08.1029.
10. Yancy CW, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;128(16):e240-e319. DOI: 10.1161/CIR.0b013e31829e8776.

11. Patel MR, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria For Diagnostic Catheterization: American College of Cardiology Foundation Appropriate Use Criteria Task Force Society for Cardiovascular Angiography and Interventions American Association for Thoracic Surgery American Heart Association, American Society of Echocardiography American Society of Nuclear Cardiology Heart Failure Society of America Heart Rhythm Society, Society of Critical Care Medicine Society of Cardiovascular Computed Tomography Society for Cardiovascular Magnetic Resonance Society of Thoracic Surgeons. *Catheterization and Cardiovascular Interventions* 2012;80(3):E50-E81. DOI: 10.1002/ccd.24467.
12. McKelvie RS, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. *Canadian Journal of Cardiology* 2013;29(2):168-181. DOI: 10.1016/j.cjca.2012.10.007.
13. Ponikowski P, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal* 2016;37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128.
14. Gersh BJ, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011;124:e783-e831. DOI: 10.1161/CIR.0b013e318223e2bd.
15. McCrindle BW, et al. Diagnosis, treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. *Circulation* 2017;135(17):e927-e999. DOI: 10.1161/CIR.0000000000000484.
16. Mehra MR, et al. International Society for Heart and Lung Transplantation Working Formulation of a Standardized Nomenclature for Cardiac Allograft Vasculopathy—2010. *International Society for Heart and Lung Transplantation. J Heart Lung Transplant* 2010;29:717-27.
17. Torres HJ, et al. Prevalence of Cardiac Allograft Vasculopathy Assessed with Coronary Angiography Versus Coronary Vascular Ultrasound and Virtual Histology. *Transplantation Proceedings* 2011;43(6):2318-2321. DOI: 10.1016/j.transproceed.2011.06.002.
18. Jessup M, et al. 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement On Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients with Advanced Heart Failure and Cardiac Transplant): A report of the ACC Competency Management Committee. *Circulation: Heart Failure* 2017;10(6):e000021. DOI: 10.1161/HHF.0000000000000021.
19. de la Torre Hernandez J.M., Hernández Hernandez F., Alfonso F., et al. (2011) Prospective Application of Pre-Defined Intravascular Ultrasound Criteria for Assessment of Intermediate Left Main Coronary Artery Lesions Results from the Multicenter LITRO Study. *J Am Coll Cardiol* 58:351-358.
20. Montero Cabezas JM, Berenguer JN, et al. Left Main Extrinsic Compression in Pulmonary Arterial Hypertension from Identification to Percutaneous Coronary Intervention Optimization. *Journal of the American College of Cardiology*. Volume 70, Issue 19, November 2017 DOI: 10.1016/j.jacc.2017.07.799.
21. Nishimura RA, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129(23):e521-e643. DOI: 10.1161/CIR.0000000000000031.
22. Shaw LJ, Peterson ED, Shaw LK, et al. Use of a Prognostic Treadmill Score in Identifying Diagnostic Coronary Disease Subgroups. Originally published 20 Oct 1998, <https://doi.org/10.1161/01.CIR.98.16.1622> *Circulation*. 1998;98:1622-1630.
23. Mark DB, Hlatky MA, Harrell FE Jr., et al. Exercise Treadmill Score for Predicting Prognosis In Coronary Artery Disease. *Ann Intern Med*. 1987;106:793- 800.



24. Amsterdam EA, et al. AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;130(25):e344–e426. DOI: 10.1161/CIR.0000000000000134.
25. Fihn SD, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis And Management of Patients with Stable Ischemic Heart Disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation* 2012;126(25):e354–e471. DOI: 10.1161/CIR.0b013e318277d6a0.
26. Raman SV, Simonetti OP, Winner MW, et al.. Cardiac Magnetic Resonance With Edema Imaging Identifies Myocardium At Risk And Predicts Worse Outcome In Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. *J Am Coll Cardiol.* 2010; 55:2480–8.
27. Deharo P, et al. Timing of Angiography and Outcomes In High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights from the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). *Circulation* 2017;136(20):1895–1907. DOI: 10.1161/CIRCULATIONAHA.117.029779.
28. Antman EM, Cohen M, Bernink PJ, et al.. The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making. *JAMA.* 2000; 284:835–42.
29. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. *Arch Intern Med.* 2003;163:2345–53.
30. Cannon CP, Weintraub WS, Demopoulos LA, et al.. Comparison of Early Invasive and Conservative Strategies in Patients With Unstable Coronary Syndromes Treated with the Glycoprotein lib/IIa Inhibitor Tirofiban. *N Engl J Med.* 2001; 344:1879–87.
31. Damman P, Hirsch A, Windhausen F, et al.. 5-year Clinical Outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable Coronary Syndromes) Trial A Randomized Comparison of An Early Invasive Versus Selective Invasive Management In Patients with Non-ST-Segment Elevation Acute Coronary Syndrome. *J Am Coll Cardiol.* 2010; 55:858–64.
32. de Winter RJ, Windhausen F, Cornel JH, et al.. Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. *N Engl J Med.* 2005; 353:1095–104.
33. Fox KA, Poole-Wilson PA, Henderson RA, et al.. Interventional versus Conservative Treatment for Patients with Unstable Angina or Non-ST-Elevation Myocardial Infarction: The British Heart Foundation RITA 3 Randomized Trial. *Randomized Intervention Trial of Unstable Angina. Lancet.* 2002; 360:743–51.
34. Mehta SR, Granger CB, Boden WE, et al.. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. *N Engl J Med.* 2009; 360:2165–75.
35. O'Donoghue M, Boden WE, Braunwald E, et al.. Early Invasive vs Conservative Treatment Strategies In Women and Men with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Meta-Analysis. *JAMA.* 2008; 300:71–80.
36. Fox KA, Clayton TC, Damman P, et al. Long-Term Outcome of a Routine Versus Selective Invasive Strategy In Patients with Non-ST-Segment Elevation Acute Coronary Syndrome a Meta-Analysis of Individual Patient Data. *J Am Coll Cardiol.* 2010;55:2435–45.
37. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA.* 2005;293:2908–17.
38. Invasive compared with Non-Invasive Treatment in Unstable Coronary Artery Disease: FRISC II Prospective Randomized Multicentre Study. FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators. *Lancet.* 1999;354:708–15.
39. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year Outcome of an Interventional Strategy in Non-ST-Elevation Acute Coronary Syndrome: The British Heart Foundation RITA 3 Randomized Trial. *Lancet.* 2005;366:914–20.

40. Maddox TM, et al. Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. *Journal of the American Medical Association* 2014;312(17):1754-1763. DOI: 10.1001/jama.2014.14681.
41. Larsen JM, Ravkilde J. Acute Coronary Angiography in Patients Resuscitated From Out-Of-Hospital Cardiac Arrest--A Systematic Review and Meta-Analysis. *Resuscitation* 2012;83(12):1427-1433. DOI: 10.1016/j.resuscitation.2012.08.337.
42. Zanuttini D, et al. Impact of Emergency Coronary Angiography on In-Hospital Outcome of Unconscious Survivors After Out-Of-Hospital Cardiac Arrest. *American Journal of Cardiology* 2012;110(12):1723-1728. DOI: 10.1016/j.amjcard.2012.08.006.
43. Lee PH, Lee JY et al. Comparison of a Simple Angiographic Approach With a Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Score-Based Approach for Left Main Coronary Artery Stenting. *Circ Cardiovasc Interv.* 2018;11:e005374. DOI: 10.1161/CIRCINTERVENTIONS.117.005374.
44. Parikh V, Agnihotri K, Kadavath S, Patel NJ, Abbott JD. Clinical Application of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention For Stable Coronary Artery Disease. *Current Cardiology Reports* 2016;18(4):32. DOI: 10.1007/s11886-016-0711-3.
45. Elwyn G, Edwards A, Kinnersley P. Shared decision-making in primary care: the neglected second half of the consultation. *Br J Gen Pract.* 1999;49(443):477-482.
46. Elwyn G, Edwards A, Kinnersley P et al. Shared decision making and the concept of equipoise: the competences of involving patients in healthcare choices. *Br J Gen Pract.* 2000;50(460):892-899.
47. Gwyn R and Elwyn G. When is a shared decision not (quite) a shared decision? Negotiating preferences in a general practice encounter. *Soc Sci Med.* 1999;49(4):437-447.
48. Elwyn G, Edwards A, Wensing M et al. Shared decision making: developing the OPTION scale for measuring patient involvement. *Qual Saf Health Care.* 2003;12(2):93-99.
49. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango) *Soc Sci Med.* 1997;44(5):681-692.
50. Charles CA, Whelan T, Gafni A. Shared treatment decision making: What does it mean to physicians? *J Clin Oncol.* 2003;21(5):932-936.
51. Murray E, Pollack L, White M et al. Clinical decision-making: Patients' preferences and experiences. *Patient Educ Couns.* 2007;65(2):189-196.
52. Braddock CH, 3rd, Fihn SD, Levinson W et al. How doctors and patients discuss routine clinical decisions. Informed decision making in the outpatient setting. *J Gen Intern Med.* 1997;12(6):339-345.
53. Wilson SR, Strub P, Buist AS et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. *Am J Respir Crit Care Med.* 2010;181(6):566-577.
54. Urowitz S, Deber R. How Consumerist Do People Want to Be? Preferred Role in Decision-Making of Individuals with HIV/AIDS. *Healthc Policy.* 2008;3(3):e168-e182.
55. White DB, Braddock CH, 3rd, Berecknyei S et al. Toward shared decision making at the end of life in intensive care units: opportunities for improvement. *Arch Intern Med.* 2007;167(5):461-467.
56. Informed Medical Decisions Foundation. Shared Decision Making and Evidence-Based Practice Unite in Sydney. 2015. Accessed on October 25, 2019 from <http://www.informedmedicaldecisions.org/2015/08/20/shared-decision-making-and-evidence-based-practice-unite-in-sydney/> Retrieved 11/09/2015.
57. Fairbairn TA, Nieman K, et al. Real-world Clinical Utility and Impact on Clinical Decision-Making of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve: Lessons from the ADVANCE Registry. *European Heart Journal*, Volume 39, Issue 41, 01 November 2018, Pages 3701-3711.
58. O'Connor AM, Llewellyn-Thomas HA, Flood AB (2004) Modifying unwarranted variations in health care: Shared decision making using patient decision aids. *Health Affairs.*
59. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation

Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. *J Am Coll Cardiol* 2012; 59:857e881.

60. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC, Stanko SJ, Watts B. ACC/AHA/SCAI/AMA-convened PCPI/ NCQA 2013 performance measures for adults undergoing percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on performance measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for performance improvement, and the National Committee for Quality Assurance. *J Am Coll Cardiol* 2014; 63:722e745.
61. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. *Circulation*. 2013; 127(7):769-781.
62. Boden WE, O'Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. *N Engl J Med*. 2007;356(15):1503-1516. doi:10.1056/NEJMoa070829
63. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2012; 172(4):312-319.
64. Patel MR, Dehmer GJ, Hirshfeld JW, et al; Coronary Revascularization Writing Group; Technical Panel; Appropriate Use Criteria Task Force; American College of Cardiology Foundation; American College of Cardiology Foundation Appropriate Use Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Thoracic Surgeons; American Heart Association; American Society of Nuclear Cardiology; Society of Cardiovascular CT. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation. *J Thorac Cardiovasc Surg*. 2012; 143 (4): 780-803.
65. Elwyn G, Barr PJ, Grande SW et al. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. *Patient Educ Couns*. 2013;93(1):102-7.
66. Elwyn G, Frosch D, Thomson R et al. Shared Decision Making: A Model for Clinical Practice. *J Gen Intern Med*. 2012;27(10):1361-7.
67. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145(3). doi:10.1161/CIR.0000000000001038
68. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European Heart Journal*. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
69. Spertus JA, Jones PG, Maron DJ, et al. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. *N Engl J Med*. 2020;382(15):1408-1419. doi:10.1056/NEJMoa1916370
70. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *The Lancet*. 2018;391(10115):31-40. doi:10.1016/S0140-6736(17)32714-9

## Documentation for Clinical Review

Please provide the following documentation:

- History and physical and/or consultation notes including:

- Angina class (Canadian Cardiovascular Society Grading of Angina Pectoris, Class I, II, III or IV)
- Unusual location of obstruction(s), unusual coronary anatomy, or unusual flow dynamics noted by the cardiologist if applicable
- Intercurrent cardiac disease (e.g., congenital heart disease, congestive heart failure, hypertrophic cardiomyopathy, kawasaki disease, post-cardiac transplant, myocardial disease, arrhythmia, valvular disease) if applicable
- Current or recent smoking history (within one year)
- Cardiologist documentation of difficult-to-control uncontrolled hypertension on maximal therapy or uncontrolled dyslipidemia on maximal therapy if applicable
- Diabetes mellitus with a first or second degree relative with premature coronary artery disease (i.e., age less than 65, MI or coronary intervention) if applicable
- Strong family history of coronary artery disease if applicable
- Prior PCI or CABG procedure if applicable
- Pertinent past procedural and surgical history
- Radiology report(s) (i.e., MRI, FFRct, CCTA)

**Post Service (in addition to the above, please include the following):**

- Results/reports of tests performed
- Procedure report(s)

## Coding

*This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.*

*The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.*

Type	Code	Description
CPT®	93454	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation
	93455	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography
	93456	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization
	93457	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization
	93458	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging

Type	Code	Description
		supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
	93459	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography
	93460	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
	93461	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography
HCPCS	C7516	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report
	C7517	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, with iliac and/or femoral artery angiography, nonselective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation
	C7518	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging, supervision, interpretation and report
	C7519	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7520	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging

Type	Code	Description
		supervision and interpretation, with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) includes intraprocedural injection(s) for bypass graft angiography with iliac and/or femoral artery angiography, nonselective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta or ipsilateral femoral or iliac artery, injection of dye, production of permanent images, and radiologic supervision and interpretation <b>(Code effective 1/1/2023)</b>
	C7521	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography with right heart catheterization with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report
	C7522	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation with right heart catheterization, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7523	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report
	C7524	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7525	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report
	C7526	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with

Type	Code	Description
		intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7527	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with endoluminal imaging of initial coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report
	C7528	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7529	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation, with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (initial coronary vessel or graft) during coronary angiography including pharmacologically induced stress
	C7552	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization with intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress, initial vessel
	C7553	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography with pharmacologic agent administration (e.g., inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed

## Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
08/01/2020	New policy
08/01/2021	Annual review. No change to policy statement.
05/01/2022	Annual review. Policy statement and guidelines updated.
11/01/2022	Policy statement and guidelines updated.
12/01/2022	Administrative update. Policy statement, guidelines and literature updated.
04/01/2023	Coding update.
09/01/2023	Annual review. Policy statement and guidelines updated.
09/01/2024	Annual review. No change to policy statement.

## Definitions of Decision Determinations

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

## Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at [www.blueshieldca.com/provider](http://www.blueshieldca.com/provider).

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: [MedPolicy@blueshieldca.com](mailto:MedPolicy@blueshieldca.com)



*Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.*

**Appendix A**

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<p><b>Elective Invasive Coronary Angiography (ICA) BSC2.13</b></p> <p><b>Policy Statement:</b> This medical policy is not intended to address prior authorization of ICA for acute coronary syndrome (ACS) or other high-risk situations as addressed in the <a href="#">Policy Guidelines</a> section below. However, services provided without prior authorization (including inpatient care) are subject to post service review and are also subject to the criteria and definitions in this policy. Documentation of why the individual is thought to have ACS or other high-risk conditions is required to meet criteria.</p> <ol style="list-style-type: none"> <li>I. Elective (NOT emergent) Invasive Coronary Angiography (ICA) and catheterization may be considered <b>medically necessary</b> when <b>any</b> of the following documentation are met:               <ol style="list-style-type: none"> <li>A. The individual is 18 years of age or younger</li> <li>B. Congenital heart disease (CHD)</li> <li>C. Heart failure (HF) (also known as Congestive Heart Failure or CHF) with reduced ejection fraction (40% or less)</li> <li>D. Hypertrophic cardiomyopathy (HCM)</li> <li>E. Kawasaki disease (KD) (also known as mucocutaneous lymph node syndrome)</li> <li>F. Post-cardiac transplant in a individual who has not undergone coronary angiography in the previous six months</li> <li>G. Pulmonary artery extrinsic compressions of left main coronary artery</li> <li>H. Valvular heart disease requiring open surgical replacement</li> <li>I. New onset or escalation of angina on optimal medical therapy and within 9 months of percutaneous coronary intervention (PCI)</li> <li>J. Intolerance of or failure to respond to optimal medical treatment (see <a href="#">Policy Guidelines section</a>)</li> </ol> </li> <li>II. Elective Invasive coronary angiography (ICA) and catheterization for known or suspected coronary artery disease (CAD) is considered <b>not</b></li> </ol>	<p><b>Elective Invasive Coronary Angiography (ICA) BSC2.13</b></p> <p><b>Policy Statement:</b> This medical policy is not intended to address prior authorization of ICA for acute coronary syndrome (ACS) or other high-risk situations as addressed in the <a href="#">Policy Guidelines</a> section below. However, services provided without prior authorization (including inpatient care) are subject to post service review and are also subject to the criteria and definitions in this policy. Documentation of why the individual is thought to have ACS or other high-risk conditions is required to meet criteria.</p> <ol style="list-style-type: none"> <li>I. Elective (NOT emergent) Invasive Coronary Angiography (ICA) and catheterization may be considered <b>medically necessary</b> when <b>any</b> of the following documentation are met:               <ol style="list-style-type: none"> <li>A. The individual is 18 years of age or younger</li> <li>B. Congenital heart disease (CHD)</li> <li>C. Heart failure (HF) (also known as Congestive Heart Failure or CHF) with reduced ejection fraction (40% or less)</li> <li>D. Hypertrophic cardiomyopathy (HCM)</li> <li>E. Kawasaki disease (KD) (also known as mucocutaneous lymph node syndrome)</li> <li>F. Post-cardiac transplant in a individual who has not undergone coronary angiography in the previous six months</li> <li>G. Pulmonary artery extrinsic compressions of left main coronary artery</li> <li>H. Valvular heart disease requiring open surgical replacement</li> <li>I. New onset or escalation of angina on optimal medical therapy and within 9 months of percutaneous coronary intervention (PCI)</li> <li>J. Intolerance of or failure to respond to optimal medical treatment (see <a href="#">Policy Guidelines section</a>)</li> </ol> </li> <li>II. Elective Invasive coronary angiography (ICA) and catheterization for known or suspected coronary artery disease (CAD) is considered</li> </ol>

POLICY STATEMENT (No changes)	
BEFORE	AFTER
<b>medically necessary</b> for all other indications not meeting the medically necessary criteria, including but not limited to the results of computed tomography coronary artery calcium scores.	<b>not medically necessary</b> for all other indications not meeting the medically necessary criteria, including but not limited to the results of computed tomography coronary artery calcium scores.